Champions Oncology Study Results Highlighted in Presentation at ASCO

Hackensack, NJ – June 5, 2013 –  Champions Oncology, Inc. (OTC : CSBR) is pleased to announce the oral presentation of a new paper, “Integrated Genomics and Avatar Mouse Models for Personalized Cancer Treatment”, at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting on June 1st in Chicago, IL.

This groundbreaking study combined deep sequencing with mouse avatar testing in 19 patients. The work, a collaborative effort between investigators at the Spanish National Cancer Research Centre, Champions Oncology and Personal Genome Diagnostics, Inc. demonstrated that most patients in the study received clinical benefit from the combination of deep sequencing and mouse avatar testing.

In the study, exome sequencing analysis was used to inform the selection of drugs that were tested in mouse avatar models for 13 patients. The results of the mouse avatar tests were used to guide treatment for these patients. 11 of the 13 patients received clinical benefit from the avatar guided therapy.

“The study results demonstrated the strong predictive power of avatar models as an investigational, personalized tool for therapeutic decision-making and their utility in helping to guide cancer treatment in the clinic,” stated Joel Ackerman, CEO of Champions Oncology. “We look forward to further testing this strategy in the coming months in several prospective, clinical validation studies, in line with our goal of developing innovative solutions in personalized oncology.”